Results 131 to 140 of about 18,310 (204)

[Rational use of antirheumatic agents].

Lijecnicki vjesnik, 1983
T, Dürrigl, B, Vrhovac
openaire   +1 more source

Prevalence and risk factors of difficult-to-treat axial spondyloarthritis: Real-life evidence from the BioSTaR database. [PDF]

Clin Rheumatol
Bodur H, Ataman Ş, Yurdakul FG, Gürer G, Akgün K, İnceoğlu LA, Sunar İ, Akgül Ö, Sezer İ, Çapkın E, Rezvani A, Yağcı İ, Duruöz MT, Çay HF, Çevik R, Göğüş F, Kamanlı A, Ecesoy H, Güler T, Şahin N, Cengiz G, Melikoğlu MA.   +21 more
europepmc   +1 more source

2. Antirheumatic Agents, 2) Biological Agents

Nihon Naika Gakkai Zasshi, 2012
openaire   +2 more sources

IgA nephropathy with rheumatoid arthritis related to adalimumab. [PDF]

CEN Case Rep
Tüfekçi B, Kardaş RC, Öğüt B, Erden A.   +3 more
europepmc   +1 more source

[Treatment of adult chronic non-bacterial osteitis in Germany : Comparison of real-world practice and current expert consensus recommendations]. [PDF]

Z Rheumatol
van Wijnen P, Klemm P, Schmidt M, Christofyllakis K, Müller-Ladner U, Assmann G.   +5 more
europepmc   +1 more source

Prompt clinical and electrophysiological remission of refractory peripheral neuropathy in long-standing rheumatoid arthritis with tocilizumab: a case report. [PDF]

Front Immunol
Huang H, Zhong X, Kuang S, Tan J, Tan L, Li B.   +5 more
europepmc   +1 more source

Tofacitinib: New drug in the therapeutic armamentarium in ocular inflammation. [PDF]

Indian J Ophthalmol
Babu K, Mooss V.
europepmc   +1 more source

INDOMETHACIN: A NEW ANTIRHEUMATIC AGENT.

Minnesota medicine, 1996
P J, BILKA, F, WOLLHEIM, R C, WILLIAMS
openaire   +1 more source

Dose reduction and discontinuation of non-tumor necrosis factor (TNF) biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for people with rheumatoid arthritis in remission or low disease activity. [PDF]

Cochrane Database Syst Rev
Li YJ, Lopez-Olivo MA, Geng Y, Tayar JH, Suarez-Almazor ME.   +4 more
europepmc   +1 more source